Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Molecular Cancer Therapeutics|March 5, 2016
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsElizabeth A Punnoose, Joel D Leverson, Franklin Peale, et al.Blood|April 28, 2012
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsDelphine Mérino, Seong L Khaw, Stefan P Glaser, et al.ACS Chemical Biology|August 30, 2016
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 MutationsAdam R Johnson, Pawan Bir Kohli, Arna Katewa, et al.Journal of Medicinal Chemistry|February 20, 2018
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical DevelopmentJames J Crawford, Adam R Johnson, Dinah L Misner, et al.Journal of Medicinal Chemistry|August 5, 2022
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1Alexander M Taylor, Chris Bailey, Lisa D Belmont, et al.Nature|March 4, 2011
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7Ingrid E Wertz, Saritha Kusam, Cynthia Lam, et al.Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.Proceedings of the National Academy of Sciences of the United States of America|February 20, 2010
Antitumor activity of an allosteric inhibitor of centromere-associated protein-EKenneth W Wood, Latesh Lad, Lusong Luo, et al.Pageof 2